The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

NeuroDerm Announces Streamlined U.S. Development Plan on ND0612H and ND0612L for the Treatment of PD


(November 11, 2015) - NeuroDerm announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company's continuous, subcutaneously delivered levodopa/carbidopa product candidates for the treatment of Parkinson's disease. Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients. Read more…



Article Archive

back